Article
Immunology
Mathieu Ferrari, Shimobi C. Onuoha, Liliane Fossati-Jimack, Alessandra Nerviani, Pedro L. Alves, Sara Pagani, Cecilia Deantonio, Federico Colombo, Claudio Santoro, Daniele Sblattero, Costantino Pitzalis
Summary: Novel tissue-specific agent BsAb shows improved therapeutic effect by targeting the arthritic synovium, providing better efficacy compared to standard treatment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Haroutyun Joulfayan, Tigran Makunts, Ruben Abagyan
Summary: Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects 1% of the global population. The use of TNF inhibitors for RA treatment may lead to adverse events, such as the onset of psoriasis. This study analyzed a large number of safety reports and provided evidence for a significant association between TNF inhibitor use and psoriasis, with varying degrees of association observed among different drugs.
SCIENTIFIC REPORTS
(2023)
Article
Medicine, General & Internal
Daniela Anghel, Carmen Adella Sirbu, Oana-Georgiana Petrache, Daniela Opris-Belinski, Maria Magdalena Negru, Violeta-Claudia Bojinca, Cristina Florentina Plesa, Florentina Ionita Radu
Summary: Videocapillaroscopy is a simple, non-invasive investigation used to study nailfold capillaries. It is commonly used for patients with Raynaud's phenomenon and systemic sclerosis, but can also be used for patients with suspected microcirculation alterations. The study aimed to identify nailfold videocapillaroscopic abnormalities in rheumatoid arthritis and psoriatic arthritis patients and analyze their correlation with 12 months of anti-TNF-α therapy. The findings showed significant improvements in capillary density, dilated and giant capillaries, elongated capillaries, and angiogenesis after 12 months of treatment, with no avascular areas found.
Article
Pediatrics
Lili Ye, Yingying Jin, Hua Huang, Fei Ding, Xuemei Xu, Chenxi Liu, Shengfang Bao, Jing Wu, Yanliang Jin
Summary: This study explored the role of DKK-1 and SOST in the pathogenesis of JIA. It was found that plasma levels of DKK-1 were significantly higher in JIA patients, especially in those with HLA-B27 positivity. After treatment, DKK-1 levels decreased significantly. However, there was no significant change in SOST levels among different JIA subtypes, before and after treatment, and healthy controls.
PEDIATRIC RESEARCH
(2023)
Article
Orthopedics
Antonio Julia, Maria Lopez-Lasanta, Francisco Blanco, Antonio Gomez, Isabel Haro, Antonio Juan Mas, Alba Erra, Ma Luz Garcia Vivar, Jordi Monfort, Simon Sanchez-Fernandez, Isidoro Gonzalez, Mercedes Alperi, Raul Castellanos-Moreira, Antonio Fernandez-Nebro, Cesar Diaz-Torne, Nuria Palau, Raquel Lastra, Jordi Llados, Raimon Sanmarti, Sara Marsal
Summary: This study revealed significant antibody interactions, including the interaction between anti-CarP and anti-PAD4, as well as between anti-CCP and RF, which are associated with treatment response in RA patients receiving anti-TNF therapy.
BMC MUSCULOSKELETAL DISORDERS
(2021)
Review
Pharmacology & Pharmacy
Ju Li, Zhongyuan Zhang, Xinhua Wu, Jie Zhou, Deqian Meng, Ping Zhu
Summary: This meta-analysis found that treatment with anti-TNF alpha agents may increase the risk of infectious adverse events while the risk of tuberculosis was not significantly different. The use of anti-TNF agents should be carefully considered based on the risk-benefit ratio suggested by the meta-analysis.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Rheumatology
Yulu Li, Xiaolan Mao, Xuemei Tang, Huawei Mao
Summary: Through the collection of relevant studies, it was found that adalimumab is superior to infliximab in terms of efficacy and safety in patients with juvenile idiopathic arthritis associated uveitis, and infliximab is more effective than etanercept without statistical difference between the two.
RHEUMATOLOGY AND THERAPY
(2021)
Article
Pharmacology & Pharmacy
Alexander Vugler, James O'Connell, Mai Anh Nguyen, Dietmar Weitz, Thomas Leeuw, Elizabeth Hickford, Alexander Verbitsky, Xiaoyou Ying, Markus Rehberg, Bruce Carrington, Mark Merriman, Andrew Moss, Jean-Marie Nicholas, Phil Stanley, Sara Wright, Tim Bourne, Yann Foricher, Daniel Brookings, Helen Horsley, Matthias Herrmann, Srinivas Rao, Markus Kohlmann, Peter Florian
Summary: This article reports the discovery and development of a potent small molecule inhibitor of TNF, SAR441566, which has shown potential as a treatment option for chronic autoimmune diseases. By stabilizing an asymmetrical form of TNF and compromising its functions, SAR441566 offers a promising alternative to established biologic drugs targeting TNF.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Tomasz Wysocki, Agnieszka Paradowska-Gorycka
Summary: Rheumatoid arthritis is a common inflammatory arthritis in which tumor necrosis factor plays a key role. However, there is variation in response to TNF-targeting drugs, which may be influenced by genetic factors. The field of pharmacogenomics offers potential for developing novel prognostic tools.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Rheumatology
Jelena Vojinovic, Ivan Foeldvari, Joke Dehoorne, Violeta Panaviene, Gordana Susic, Gerd Horneff, Valda Stanevicha, Katarzyna Kobusinska, Zbigniew Zuber, Bogna Dobrzyniecka, Jonathan Akikusa, Tadej Avcin, Cecilia Borlenghi, Edmund Arthur, Svitlana Y. Tatulych, Chuanbo Zang, Vassilis Tsekouras, Bonnie Vlahos, Alberto Martini, Nicolino Ruperto
Summary: CLIPPER2 is an 8-year study on the safety and efficacy of etanercept in patients with juvenile idiopathic arthritis (JIA). The study found that etanercept treatment was well tolerated and effective in these patients.
Article
Rheumatology
J. Baer, J. Klotsche, I Foeldvari
Summary: This study evaluated the effectiveness of SEC in patients with anti-TNF non-responder ERA. The results showed that SEC was effective in treating ERA, but the 150 mg dose may be insufficient and most patients required escalation to the 300 mg dose.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2022)
Review
Biotechnology & Applied Microbiology
Mrinalini Dey, Sizheng Steven Zhao, Robert J. Moots
Summary: TNF inhibitors have revolutionized the treatment of rheumatic diseases, but their high acquisition cost has limited their use. The development of biosimilar TNFis has provided more cost-effective access to effective therapies. Additionally, the introduction of targeted synthetic disease-modifying drugs has offered cheaper and equally effective treatments for rheumatic diseases, changing the treatment landscape.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2021)
Review
Medicine, General & Internal
Judith A. Smith, Ruben Burgos-Vargas
Summary: Some studies suggest that children with juvenile onset spondyloarthritis have a relatively poor outcome compared to other juvenile idiopathic arthritis categories, but new therapies such as TNF inhibitors offer hope for improving disease prognosis.
FRONTIERS IN MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Cecilia Beatrice Chighizola, Matteo Ferrito, Luca Marelli, Irene Pontikaki, Paolo Nucci, Elisabetta Miserocchi, Roberto Caporali
Summary: Juvenile idiopathic arthritis (JIA) and multiple sclerosis (MS) have been associated with each other, possibly triggered by anti-TNF-alpha drugs. However, there have been limited reports on the association between MS and JIA, indicating the need for further research to establish their relationship.
Article
Medicine, General & Internal
Boglarka Soos, Miklos Fagyas, Agnes Horvath, Edit Vegh, Anita Pusztai, Monika Czokolyova, Alexandra Csongradi, Attila Hamar, Zsofia Petho, Nora Bodnar, Gyoergy Kerekes, Katalin Hodosi, Eva Szekanecz, Szilvia Szamosi, Sandor Szanto, Gabriella Szucs, Zoltan Papp, Zoltan Szekanecz
Summary: The study revealed that anti-TNF therapy may increase ACE and ACE2 levels in the sera of RA and AS patients, and these levels are associated with disease duration, markers of inflammation, and vascular pathophysiology. The changes in ACE and ACE2 are influenced by treatment and other factors such as RF or FMD.
FRONTIERS IN MEDICINE
(2022)